SAB Biotherapeutics, Inc.
NASDAQ Global MarketTotal Valuation
SAB Biotherapeutics, Inc. carries a market capitalization of 32.12M, placing it among publicly traded companies globally. Its enterprise value stands at -7.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 32.12M |
| Enterprise Value | -7.37M |
Share Statistics
SAB Biotherapeutics, Inc. currently has 75.74M shares outstanding.
| Shares Outstanding | 75.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
SAB Biotherapeutics, Inc. trades at a trailing price-to-earnings ratio of 2.84.
| PE Ratio | 2.84 |
| PS Ratio | N/A |
| PB Ratio | -0.72 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | -3.64 |
| P/OCF Ratio | -1.83 |
Financial Position
SAB Biotherapeutics, Inc. maintains a current ratio of 11.45, meaning it holds 11.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.72, indicating elevated leverage, while an interest coverage ratio of -235.73 demonstrates limited ability to service its debt obligations.
| Current Ratio | 11.45 |
| Quick Ratio | 11.06 |
| Debt / Equity | 2.72 |
| Debt / EBITDA | -0.11 |
| Interest Coverage | -235.73 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -0.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -19.40 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
SAB Biotherapeutics, Inc.'s stock has gained approximately 79.67914% over the past 52 weeks. The 50-day moving average sits at 3.76, while the 200-day moving average is 3.42.
| Beta (5Y) | N/A |
| 52-Week Price Change | 79.67914% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 3.42 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -55.12M, while operating income came in at -58.18M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -58.18M |
| Pretax Income | -398,429.00 |
| Net Income | -398,429.00 |
| EBITDA | -55.12M |
| EBIT | -58.18M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
SAB Biotherapeutics, Inc. holds 107.39M in cash and equivalents against 6.17M in total debt, resulting in a net debt position of -20.52M. Total book value stands at -129.76M, with working capital of 102.93M providing operational flexibility.
| Cash & Cash Equivalents | 107.39M |
| Total Debt | 6.17M |
| Net Debt | -20.52M |
| Equity (Book Value) | -129.76M |
| Book Value Per Share | -5.30 |
| Working Capital | 102.93M |
Cash Flow
SAB Biotherapeutics, Inc. produced -51.25M in operating cash flow over the past twelve months. After subtracting -1.92M in capital expenditures, free cash flow totaled -53.17M - equivalent to -2.17 per share.
| Operating Cash Flow | -51.25M |
| Capital Expenditures | -1.92M |
| Free Cash Flow | -53.17M |
| FCF Per Share | -2.17 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -275.32 |
| FCF Yield | -27.46 |
Stock Splits
SAB Biotherapeutics, Inc.'s most recent stock split took place on January 5, 2024 with a 10:1 split ratio.
| Last Split Date | 1/5/2024 |
| Split Ratio | 10:1 |
Scores
SAB Biotherapeutics, Inc. posts an Altman Z-Score of 1.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.65 |